Key result
Resveratrol attenuates diabetic cardiomyopathy and oxidative damage in preclinical models by restoring Nrf2 expression.
Why the study?
Does oral resveratrol prevent diabetic cardiomyopathy, cardiac fibrosis, and oxidative stress via Nrf2 signaling in a mouse model of streptozotocin-induced type 1 diabetes?
Does oral resveratrol prevent diabetic cardiomyopathy, cardiac fibrosis, and oxidative stress via Nrf2 signaling in a mouse model of streptozotocin-induced type 1 diabetes?
In a type 1 diabetic mouse model, early oral resveratrol administration prevented diabetic cardiomyopathy, fibrosis, and oxidative stress for up to 6 months in part by restoring cardiac Nrf2 expression and transcriptional activity.
Answers are grounded in this paper and cite their sources.
Supports Nrf2-targeted therapies in diabetic cardiomyopathy models; leaves open human translation and requires prospective trials.
OBJECTIVE: This study investigated if resveratrol ameliorates diabetic cardiomyopathy by targeting associated oxidative stress mechanisms. METHOD: Type 1 diabetes mellitus (DM) in FVB mice was induced by several intraperitoneal injections of a low dose of streptozotocin. Hyperglycemic and age-matched control mice were given resveratrol (10 mg/kg per day) for 1 month and subsequently monitored for an additional 6 months. Mice were assigned to four groups: control, resveratrol, DM, and DM/resveratrol. Cardiac function and blood pressure were assessed at 1, 3, and 6 months after DM induction. Oxidative damage and cardiac fibrosis were analyzed by histopathology, real-time PCR, and Western blot. RESULT: Mice in the DM group exhibited increased blood glucose levels, cardiac dysfunction, and high blood pressure at 1, 3, and 6 months after DM induction. Resveratrol did not significantly affect blood glucose levels and blood pressure; however, resveratrol attenuated cardiac dysfunction and hypertrophy in DM mice. Resveratrol also reduced DM-induced fibrosis. In addition, DM mice hearts exhibited increased oxidative damage, as evidenced by elevated accumulation of 3-nitrotyrosine and 4-hydroxynonenal, which were both attenuated by resveratrol. Mechanistically, resveratrol increased NFE2-related factor 2 (Nrf2) expression and transcriptional activity, as well as Nrf2's downstream antioxidative targets. CONCLUSION: We demonstrated that resveratrol prevents DM-induced cardiomyopathy, in part, by increasing Nrf2 expression and transcriptional activity.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) studied Diabetic cardiomyopathy in streptozotocin-induced type 1 diabetes mellitus (mouse model) (n=72). Resveratrol vs. Untreated diabetic mice (DM) and sodium citrate buffer-injected controls was evaluated on Cardiac function (ejection fraction, fractional shortening, LV dimensions/hypertrophy), cardiac fibrosis, oxidative damage (3-NT, 4-HNE), and Nrf2 expression/activity (p=<0.05). Resveratrol attenuated diabetic cardiac dysfunction, hypertrophy, fibrosis, and oxidative damage while restoring cardiac Nrf2 expression in diabetic mice.
Synapse has enriched 10 related papers. Consider them for comparative context: